- Home
- SAN vs TMO Comparison
SAN vs TMO Comparison
Compare SAN & TMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SAN | TMO |
|---|---|---|
| Founded | 1857 | 1956 |
| Country | Spain | United States |
| Employees | 185279 | N/A |
| Industry | Commercial Banks | Industrial Machinery/Components |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.6B | 223.0B |
| IPO Year | 1994 | 1996 |
Fundamental Metrics
Financial Performance| Metric | SAN | TMO |
|---|---|---|
| Price | $14.34 | $647.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 18 |
| Target Price | N/A | ★ $636.00 |
| AVG Volume (30 Days) | ★ 9.4M | 1.7M |
| Earning Date | 04-29-2026 | 04-23-2026 |
| Dividend Yield | ★ 1.54% | 0.40% |
| EPS Growth | N/A | ★ 7.32 |
| EPS | N/A | ★ 9.10 |
| Revenue | N/A | ★ $20,918,000,000.00 |
| Revenue This Year | $34.53 | $6.55 |
| Revenue Next Year | $6.55 | $5.11 |
| P/E Ratio | ★ $11.21 | $72.34 |
| Revenue Growth | N/A | ★ 14.47 |
| 52 Week Low | $9.62 | $435.27 |
| 52 Week High | $15.00 | $663.57 |
Technical Indicators
Market Signals| Indicator | SAN | TMO |
|---|---|---|
| Relative Strength Index (RSI) | 45.57 | 68.86 |
| Support Level | $14.22 | $589.71 |
| Resistance Level | $14.39 | N/A |
| Average True Range (ATR) | 0.19 | 14.24 |
| MACD | -0.06 | 2.54 |
| Stochastic Oscillator | 3.57 | 83.37 |
Price Performance
Historical ComparisonAbout SAN Banco Santander S.A. Sponsored ADR (Spain)
Santander runs five global businesses: retail and commercial banking, corporate and investment banking, wealth management and insurance, payments, and a digital platform Openbank. Spain is the largest single profit contributor, followed by Brazil, the United States, Mexico and the United Kingdom.
About TMO Thermo Fisher Scientific Inc
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).